We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Bactiguard Holding Ab | LSE:0QV2 | London | Ordinary Share | SE0005878741 | BACTIGUARD HOLDING ORD SHS |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 24.10 | 0.00 | 01:00:00 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Health & Allied Services,nec | 223.17M | -138.38M | -4.4576 | -5.41 | 748.16M |
From Apr 2019 to Apr 2024
STOCKHOLM, Sept. 10, 2019 /PRNewswire/ -- Bactiguard's indwelling urinary catheters (Foleys) are now approved for reimbursement in the Netherlands, which means that healthcare providers in the home care market can provide patients with Bactiguard's products for infection prevention and improve their quality of life.
To be able to sell medical devices to the Dutch home care providers in a broader scale, the products must be reimbursed. Bactiguard's Foleys are now included, which means that our partner in the Netherlands, Mediplast, can start to offer the products to a larger group of patients.
"The homecare market offers the biggest market potential for Foley catheters in the Netherlands. Now that our products are reimbursed, we will increase the pace of expansion in the country", says Jonas Östregård, SVP Sales & Marketing at Bactiguard.
"I am so pleased to be able to offer Bactiguard's infection preventive products to Dutch home care patients and thereby reduce the risk of hospital acquired infections and improve their quality of life. Now that the products are reimbursed, we can approach the homecare companies with a cost-effective solution for long term catheterized patients, which wasn't possible before," says Wil Graus, Sales and Managing Director at Mediplast Benelux.
Bactiguard and Mediplast have been partners since October 2018. The original agreement covered sales and distribution of Bactiguard's product portfolio for infection prevention (BIP) in Scandinavia. Already in December the same year, the partnership was extended to include Belgium, the Netherlands and Luxembourg.
Bactiguard's infection protection (BIP) solutions, which include products for the urinary tract, blood stream and respiratory tract, reduce the risk of healthcare associated infections, the use of antibiotics and thus the spread of multi-resistant bacteria.
For further information, please contact:
Jonas Östregård
SVP Sales & Marketing
cell phone: +46-70-521-13-88
This information was brought to you by Cision http://news.cision.com
https://news.cision.com/bactiguard-holding-ab--publ-/r/bactiguard-s-urinary-catheters-approved-for-reimbursement-in-the-dutch-market,c2899465
The following files are available for download:
https://mb.cision.com/Main/9686/2899465/1102960.pdf | 190910 Bactiguard’s urinary catheters approved for reimbursement in the Dutch market |
Copyright 2019 PR Newswire
1 Year Bactiguard Holding Ab Chart |
1 Month Bactiguard Holding Ab Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
